Sign in
Active, not recruitingPhase 2

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Key facts

Who runs it
Centre for Addiction and Mental Health
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
36 people, planned
Started
16 Aug 2024
Expected to end
31 Jan 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Oral solution
Record updated
2 November 2026

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Meets DSM-5 criteria for AUD
  • Meets drinking criteria of average weekly consumption > 10 standard drinks for women and > 15 standard drinks for men over the past 90 days
  • Willing to take study medication and participate in laboratory sessions requiring self-administration of alcohol
  • Agrees not to use cannabis or illicit drugs during the study period
  • Able to communicate and provide informed consent in English
  • Alanine Aminotransferase (ALT) and Aspartate Transaminase (AST) level should not be more than 2 times the upper normal limit, and bilirubin should not be more than 1.5 times the upper normal limit
  • Enrolled in the Ontario Health Insurance Plan (OHIP)
  • Willing and able to safely abstain from alcohol for at least 12 hours prior to the eligibility and alcohol self-administration visit
  • Individuals who are capable of becoming pregnant: agree to the use of highly effective contraception during study participation and for an additional 28 days after the end of cannabidiol administration

Who cannot take part

  • Having any clinical condition, drug sensitivity, or prior therapy which, in the investigator's opinion, makes the participant unsuitable for the study
  • Current medical conditions, prescriptions, or over the counter medications that interfere with receiving the study drug or alcohol (based on the study physician's assessment)
  • Recent recreational drug use (assessed via urine toxicology screen) other than alcohol and nicotine products
  • Currently in treatment for AUD (e.g. Alcoholics Anonymous, group therapy, individual therapy, on anticraving medication)
  • History of severe alcohol withdrawal including withdrawal seizures, alcoholic hallucinosis, or delirium tremens
  • Any history of seizures
  • Serious unstable medical condition, including severe hepatic abnormalities
  • Severe mental illness (e.g. active psychosis with ongoing delusions and/or hallucinations, active manic or hypomanic episodes, evidence of a major neurocognitive disorder, etc.) and other substance use disorders (moderate or severe; excluding tobacco use disorder) as determined by the qualified investigator
  • History of hypersensitivity to CBD
  • Clinical Institute Withdrawal Assessment (CIWA-Ar) score of 10 or above upon initial assessment
  • Experiencing active suicidal ideation within the past 1 month and/or suicide attempt within the past 6 months
  • Current use of CBD products or use of CBD products within the past month
  • Self-report of significant alcohol-induced flushing after 1-2 drinks (a proxy for aldehyde dehydrogenase deficiency)
  • Currently pregnant or breastfeeding or intending to become pregnant or breastfeed
  • Currently institutionalized which refers to a person who lives in an institutional collective dwelling, such as a hospital, nursing home or prison, including a resident under custody (e.g., patient or inmate)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.

The 2 groups in the trial

  • CannabidiolTreatment being tested

    10-day supply of 600 mg of CBD, taken orally twice daily

    Treatment: Oral solution

  • PlaceboPlacebo, for comparison

    10-day supply of 600 mg of placebo, taken orally twice daily

    Treatment: Oral solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder: A Human Laboratory Study
Record updated
2 November 2026